6r2s: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6r2s' size='340' side='right'caption='[[6r2s]], [[Resolution|resolution]] 3.04Å' scene=''> | <StructureSection load='6r2s' size='340' side='right'caption='[[6r2s]], [[Resolution|resolution]] 3.04Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6r2s]] is a 3 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6r2s]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Plasmodium_vivax_Sal-1 Plasmodium vivax Sal-1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6R2S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6R2S FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.04Å</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6r2s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6r2s OCA], [https://pdbe.org/6r2s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6r2s RCSB], [https://www.ebi.ac.uk/pdbsum/6r2s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6r2s ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/PVDR_PLAVS PVDR_PLAVS] Binds to the human erythrocytes Duffy blood group determinant. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 18: | Line 18: | ||
</div> | </div> | ||
<div class="pdbe-citations 6r2s" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6r2s" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Erythrocyte binding antigen|Erythrocyte binding antigen]] | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
*[[3D structures of human antibody|3D structures of human antibody]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Plasmodium vivax Sal-1]] | ||
[[Category: Barber | [[Category: Barber NM]] | ||
[[Category: Higgins | [[Category: Higgins MK]] | ||
Revision as of 15:13, 24 January 2024
The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9
Structural highlights
FunctionPVDR_PLAVS Binds to the human erythrocytes Duffy blood group determinant. Publication Abstract from PubMedThe most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.,Rawlinson TA, Barber NM, Mohring F, Cho JS, Kosaisavee V, Gerard SF, Alanine DGW, Labbe GM, Elias SC, Silk SE, Quinkert D, Jin J, Marshall JM, Payne RO, Minassian AM, Russell B, Renia L, Nosten FH, Moon RW, Higgins MK, Draper SJ Nat Microbiol. 2019 May 27. pii: 10.1038/s41564-019-0462-1. doi:, 10.1038/s41564-019-0462-1. PMID:31133755[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||